Cargando…
MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment
Next to anticoagulation, pulmonary vein isolation (PVI) is the most important interventional procedure in the treatment of atrial fibrillation (AF). Despite widespread clinical application of this therapy, patients often require multiple procedures to reach clinical success. In contrast to conventio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861091/ https://www.ncbi.nlm.nih.gov/pubmed/31798911 http://dx.doi.org/10.1136/openhrt-2019-001014 |
_version_ | 1783471282325553152 |
---|---|
author | Wenker, Steven van Lieshout, Chris Frederix, Geert van der Heijden, Jeroen Loh, Peter Chamuleau, Steven A J van Slochteren, Frebus |
author_facet | Wenker, Steven van Lieshout, Chris Frederix, Geert van der Heijden, Jeroen Loh, Peter Chamuleau, Steven A J van Slochteren, Frebus |
author_sort | Wenker, Steven |
collection | PubMed |
description | Next to anticoagulation, pulmonary vein isolation (PVI) is the most important interventional procedure in the treatment of atrial fibrillation (AF). Despite widespread clinical application of this therapy, patients often require multiple procedures to reach clinical success. In contrast to conventional imaging modalities, MRI allows direct visualisation of the ablation lesion. Therefore, the use of real-time MRI to guide cardiac electrophysiology procedures may increase clinical effectiveness. An essential aspect, from a decision-making point of view, is the effect on costs and the potential cost-effectiveness of new technologies. Generally, health technology assessment (HTA) studies are performed when innovations are close to clinical application. However, early stage HTA can inform users, researchers and funders about the ultimate clinical and economic potential of a future innovation. Ultimately, this can guide funding allocation. In this study, we performed an early HTA evaluate MRI-guided PVIs. METHODS: We performed an economic evaluation using a decision tree with a time-horizon of 1 year. We calculated the clinical effectiveness (defined as the proportion of patients that is long-term free of AF after a single procedure) required for MRI-guided PVI to be cost-effective compared with conventional treatment. RESULTS: Depending on the cost-effectiveness threshold (willingness to pay for one additional quality-of-life adjusted life year (QALY), interventional MRI (iMRI) guidance for PVI can be cost-effective if clinical effectiveness is 69.8% (at €80 000/QALY) and 77.1% (at €20 000/QALY), compared with 64% for fluoroscopy-guided procedures. CONCLUSION: Using an early HTA, we established a clinical effectiveness threshold for interventional MRI-guided PVIs that can inform a clinical implementation strategy. If crucial technologies are developed, it seems plausible that iMRI-guided PVIs will be able to reach this threshold. |
format | Online Article Text |
id | pubmed-6861091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-68610912019-12-03 MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment Wenker, Steven van Lieshout, Chris Frederix, Geert van der Heijden, Jeroen Loh, Peter Chamuleau, Steven A J van Slochteren, Frebus Open Heart Health Care Delivery, Economics and Global Health Care Next to anticoagulation, pulmonary vein isolation (PVI) is the most important interventional procedure in the treatment of atrial fibrillation (AF). Despite widespread clinical application of this therapy, patients often require multiple procedures to reach clinical success. In contrast to conventional imaging modalities, MRI allows direct visualisation of the ablation lesion. Therefore, the use of real-time MRI to guide cardiac electrophysiology procedures may increase clinical effectiveness. An essential aspect, from a decision-making point of view, is the effect on costs and the potential cost-effectiveness of new technologies. Generally, health technology assessment (HTA) studies are performed when innovations are close to clinical application. However, early stage HTA can inform users, researchers and funders about the ultimate clinical and economic potential of a future innovation. Ultimately, this can guide funding allocation. In this study, we performed an early HTA evaluate MRI-guided PVIs. METHODS: We performed an economic evaluation using a decision tree with a time-horizon of 1 year. We calculated the clinical effectiveness (defined as the proportion of patients that is long-term free of AF after a single procedure) required for MRI-guided PVI to be cost-effective compared with conventional treatment. RESULTS: Depending on the cost-effectiveness threshold (willingness to pay for one additional quality-of-life adjusted life year (QALY), interventional MRI (iMRI) guidance for PVI can be cost-effective if clinical effectiveness is 69.8% (at €80 000/QALY) and 77.1% (at €20 000/QALY), compared with 64% for fluoroscopy-guided procedures. CONCLUSION: Using an early HTA, we established a clinical effectiveness threshold for interventional MRI-guided PVIs that can inform a clinical implementation strategy. If crucial technologies are developed, it seems plausible that iMRI-guided PVIs will be able to reach this threshold. BMJ Publishing Group 2019-11-11 /pmc/articles/PMC6861091/ /pubmed/31798911 http://dx.doi.org/10.1136/openhrt-2019-001014 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Health Care Delivery, Economics and Global Health Care Wenker, Steven van Lieshout, Chris Frederix, Geert van der Heijden, Jeroen Loh, Peter Chamuleau, Steven A J van Slochteren, Frebus MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title | MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title_full | MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title_fullStr | MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title_full_unstemmed | MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title_short | MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment |
title_sort | mri-guided pulmonary vein isolation for atrial fibrillation: what is good enough? an early health technology assessment |
topic | Health Care Delivery, Economics and Global Health Care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861091/ https://www.ncbi.nlm.nih.gov/pubmed/31798911 http://dx.doi.org/10.1136/openhrt-2019-001014 |
work_keys_str_mv | AT wenkersteven mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT vanlieshoutchris mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT frederixgeert mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT vanderheijdenjeroen mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT lohpeter mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT chamuleaustevenaj mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment AT vanslochterenfrebus mriguidedpulmonaryveinisolationforatrialfibrillationwhatisgoodenoughanearlyhealthtechnologyassessment |